Ventyx Biosciences reported Phase II data for oral NLRP3 inhibitor VTX‑3232 showing rapid, large reductions in inflammatory biomarkers. The company said VTX‑3232 monotherapy cut hsCRP by roughly 78% over 12 weeks with an almost 80% drop within the first week and produced statistically significant reductions in IL‑6, Lp(a), fibrinogen and liver inflammation markers; safety and tolerability were acceptable. The readout drove sharp share gains and has sparked discussions about partnering the asset for cardiovascular indications, while highlighting NLRP3 inhibition as a cross‑discipline inflammation strategy with applications in heart disease and neurodegeneration.